This inventor holds 1 USPTO granted patent. Top assignees: Sandia Corporation, The University of New Mexico. Active years: 2013.
Company Filing History:
1 out of 1,769 
1 out of 942 
Years Active: 2013
Title: Iming L Chen: Innovator in Pediatric Leukemia Research
Introduction
Iming L Chen is a notable inventor based in Albuquerque, NM (US). He has made significant contributions to the field of pediatric oncology, particularly in the area of acute lymphoblastic leukemia (ALL). His work focuses on identifying genetic markers that can help in diagnosing and treating high-risk cases of B-precursor ALL.
Latest Patents
Iming L Chen holds a patent titled "Identification of novel subgroups of high-risk pediatric precursor B acute lymphoblastic leukemia, outcome correlations and diagnostic and therapeutic methods related to same." This invention relates to the identification of genetic markers in patients with high-risk B-precursor acute lymphoblastic leukemia (B-ALL) and explores their relationship to therapeutic outcomes. The patent also encompasses diagnostic and prognostic methods utilizing these genetic markers, along with kits that provide microchips and/or immunoreagents for analyzing leukemia patients. He has 1 patent to his name.
Career Highlights
Throughout his career, Iming L Chen has worked with prominent organizations such as Sandia Corporation and the University of New Mexico. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Susan R Atlas and Cheryl L Willman. Their collaborative efforts have further advanced the understanding and treatment of pediatric leukemia.
Conclusion
Iming L Chen's innovative work in identifying genetic markers for high-risk pediatric leukemia has the potential to significantly improve diagnostic and therapeutic methods. His contributions to the field are invaluable and continue to pave the way for advancements in cancer treatment.